Discovery of Cyclic Acylguanidines as Highly Potent and Selective β-Site Amyloid Cleaving Enzyme (BACE) Inhibitors: Part I—Inhibitor Design and Validation
Zhaoning Zhu(Merck & Co., Inc., Rahway, NJ, USA (United States)), John C. Hunter, Z. J. Sun, Yuanzan Ye, Leonard Favreau(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Czarniecki(Merck & Co., Inc., Rahway, NJ, USA (United States)), J.K.Y. Wong, Eric M. Parker(University of New Hampshire), Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), William J. Greenlee, Reshma Kuvelkar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared N. Cumming(Merck & Co., Inc., Rahway, NJ, USA (United States)), Johannes Voigt, Xia Chen, Daniel F. Wyss, Elizabeth M. Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), Corey Strickland(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yu‐Sen Wang, Lingyan Wang(Fujian Medical University), Brian A. McKittrick(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 121
Related Papers
Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation
|Journal of Biological Chemistry|2004|716
Transcriptional regulation of the rat NAD(P)H:quinone reductase gene
|Journal of Biological Chemistry|1991|500
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
|Journal of Pharmacology and Experimental Therapeutics|2015|336
Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells.
|Journal of Biological Chemistry|1991|283